Table 4.
Efficacy and toxicity of foscarnet
| Patients | Overall | 1st line | 2nd/3th line | Single agent | Combined |
|---|---|---|---|---|---|
| 97 | 62 | 35 | 84 | 13 | |
| Therapy duration, days | 14 | 14 | 15 | 13 | 22 |
| Response, n | 70 | 42 | 28 | 57 | 13 |
| Time to response, days | 7 | 8 | 6 | 7 | 9 |
| CMV viral load pp65 | |||||
| N of pos cells (median) | 6 | 4 | 8 | 4 | 10 |
| Range | (1–987) | (1–836) | (1–987) | (1–987) | (1–138) |
| CMV viral load PCR | |||||
| ×103 (median) | 3.4 | 2.3 | 66.8 | 33.9 | – |
| Range | (1.1–143) | (1.1–36.2) | (9.2–142.6) | (1.1–142.6) | – |
| Foscarnet | |||||
| Median dose (mg/Kg) | 143 | 150 | 88 | 143 | NA |
| Range | 35–200 | 50–200 | 35–180 | 35–200 | |
| Renal impairment, n | 13 (14%) | 9 (15%) | 4 (11%) | 12 (15%) | 1 (8%) |
| Leukopenia, n | 11 (14%) | 6 (12%) | 5 (19%) | 9 (13%) | 2 (22%) |
| Neutropenia, n | 20 (26%) | 11 (22%) | 9 (33%) | 16 (24%) | 4 (44%) |
| Thrombocytopenia, n | 28 (36%) | 18 (36%) | 10 (37%) | 22 (32%) | 6 (67%) |
| Anemia, n | 6 (8%) | 5 (10%) | 1 (4%) | 5 (7%) | 1 (11%) |
NA not available